Antidiabetic activity of N-(6-substituted-1,3-benzothiazol-2-yl)benzenesulfonamides

被引:107
作者
Moreno-Diaz, Hermenegilda [2 ]
Villalobos-Molina, Rafael [1 ]
Ortiz-Andrade, Rolffy [2 ]
Diaz-Coutino, Daniel [3 ]
Medina-Franco, Jose Luis [4 ]
Webster, Scott P. [5 ]
Binnie, Margaret [5 ]
Estrada-Soto, Samuel [1 ,2 ]
Ibarra-Barajas, Maximiliano [1 ]
Leon-Rivera, Ismael [3 ]
Navarrete-Vazquez, Gabriel [1 ,2 ]
机构
[1] Univ Nacl Autonoma Mexico, Unidad Biomed, FES Iztacala, Mexico City 54090, DF, Mexico
[2] Univ Autonoma Estado Morelos, Fac Farm, Cuernavaca 62209, Morelos, Mexico
[3] Univ Autonoma Estado Morelos, Ctr Invest Quim, Cuernavaca 62209, Morelos, Mexico
[4] Torrey Pines Inst Mol Studies, Ft Pierce, FL 34946 USA
[5] Univ Edinburgh, Endocrinol Unit, Ctr Cardiovasc Sci, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland
关键词
diabetes; benzothiazole; streptozotocin-nicotinamide model;
D O I
10.1016/j.bmcl.2008.03.086
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
N-(6-Substituted-1,3-benzothiazol-2-yl)benzenesulfonamide derivatives 1-8 were synthesized and evaluated for their in vivo antidiabetic activity in a non-insulin-dependent diabetes mellitus rat model. Several compounds synthesized showed significant lowering of plasma glucose level in this model. As a possible mode of action, the compounds were in vitro evaluated as 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) inhibitors. The most active compounds (3 and 4) were docked into the crystal structure of 11 beta-HSD1. Docking results indicate potential hydrogen bond interactions with catalytic amino acid residues. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2871 / 2877
页数:7
相关论文
共 25 条
[1]
Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs.: Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1 [J].
Barf, T ;
Vallgårda, J ;
Emond, R ;
Häggström, C ;
Kurz, G ;
Nygren, A ;
Larwood, V ;
Mosialou, E ;
Axelsson, K ;
Olsson, R ;
Engblom, L ;
Edling, N ;
Rönquist-Nii, Y ;
Öhman, B ;
Alberts, P ;
Abrahmsén, L .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) :3813-3815
[2]
The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[3]
11β-hydroxysteroid dehydrogenase type 1 inhibitors [J].
Boyle, Craig D. ;
Kowalski, Timothy J. ;
Zhang, Lili .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 41, 2006, 41 :127-140
[4]
11β-hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases [J].
Fotsch, C ;
Askew, BC ;
Chen, JJ .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (03) :289-303
[5]
VMD: Visual molecular dynamics [J].
Humphrey, W ;
Dalke, A ;
Schulten, K .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 1996, 14 (01) :33-38
[6]
Development and validation of a genetic algorithm for flexible docking [J].
Jones, G ;
Willett, P ;
Glen, RC ;
Leach, AR ;
Taylor, R .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 267 (03) :727-748
[7]
Oral antidiabetic agents - Current role in type 2 diabetes mellitus [J].
Krentz, AJ ;
Bailey, CJ .
DRUGS, 2005, 65 (03) :385-411
[8]
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].
Lipinski, CA ;
Lombardo, F ;
Dominy, BW ;
Feeney, PJ .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25
[9]
PASS-predicted design, synthesis and biological evaluation of cyclic nitrones as nootropics [J].
Marwaha, Alka ;
Goel, R. K. ;
Mahajan, Mohinder P. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (18) :5251-5255
[10]
Experimental NIDDM - Development of a new model in adult rats administered streptozotocin and nicotinamide [J].
Masiello, P ;
Broca, C ;
Gross, R ;
Roye, M ;
Manteghetti, M ;
Hillaire-Buys, D ;
Novelli, M ;
Ribes, G .
DIABETES, 1998, 47 (02) :224-229